Nucleotide supplementation may improve sleep quality in older adults aged 60-70 years
This randomized controlled trial (TALENTs) enrolled 122 community-dwelling adults aged 60-70 years, with nearly half having room for improvement in sleep quality at baseline. The study will evaluate changes in sleep quality from baseline to 4 months as part of a comprehensive geriatric health assessment, comparing a nucleotide intervention group to a placebo control group.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Nucleotide supplementation may improve sleep quality in older adults aged 60-70 years The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 42/100 (low).
The Claim
Nucleotide supplementation may improve sleep quality in older adults aged 60-70 years
This conclusion is most relevant to: Community-dwelling older adults aged 60-70 years, predominantly female (67.21%), with pre-frailty and at least one chronic condition.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Targeting Aging and Longevity with Exogenous Nucleotides (TALENTs): Rationale, Design, and Baseline Characteristics from a Randomized Controlled Trial in Older Adults. (Nutrients, 2024) —
How It Works
The proposed biological pathway:
- ▸Nucleotides are absorbed and utilized by cells
- ▸They support cellular processes including DNA repair and immune function
- ▸Improved cellular health may reduce inflammation and oxidative stress
- ▸Result: Potential improvement in sleep quality and other aging-related outcomes
Who Might Benefit
Evidence fit by population:
- ▸Community-dwelling older adults aged 60-70 years, predominantly female (67.21%), with pre-frailty and at least one chronic condition
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Baseline sleep quality was not severely impaired (mean scores within normal range), limiting generalizability to clinical insomnia populations
- ▸The study is ongoing; only baseline characteristics are reported, so no causal conclusions can yet be drawn
- ▸The sample is predominantly female, which may limit generalizability to male older adults
Frequently Asked Questions
What is the TALENTs trial?▼
TALENTs is a randomized, double-blinded, placebo-controlled trial testing whether exogenous nucleotide supplements can act as an anti-aging intervention in older adults aged 60-70 years.
How is sleep quality measured in this study?▼
Sleep quality is assessed as part of a comprehensive geriatric health evaluation, though the specific instrument (e.g., PSQI) is not detailed in the abstract.
What were the baseline sleep characteristics of participants?▼
Nearly half of participants had room for improvement in sleep quality, but mean scores were within the normal range, indicating mild rather than severe sleep issues.
When will results on sleep quality be available?▼
The study measures outcomes at 2 months and 4 months of intervention; results are pending as only baseline data are reported in this paper.
References
- 1.Wang S, Song L, Fan R, Chen Q, You M, Cai M, Wu Y, Li Y, Xu M. “Targeting Aging and Longevity with Exogenous Nucleotides (TALENTs): Rationale, Design, and Baseline Characteristics from a Randomized Controlled Trial in Older Adults..” Nutrients, 2024. PMID: 38732590 DOI: 10.3390/nu16091343